Literature DB >> 26398092

Early Patterns of Sofosbuvir Utilization by State Medicaid Programs.

Joshua M Liao1, Michael A Fischer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26398092     DOI: 10.1056/NEJMc1506108

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Short-Term Incidence of Sequelae of HCV Infection Among Medicaid Beneficiaries in Oregon.

Authors:  Kazuaki Jindai; Courtney Crawford; Ann R Thomas
Journal:  Public Health Rep       Date:  2018-12-03       Impact factor: 2.792

2.  Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.

Authors:  Kohtaro Ooka; James J Connolly; Joseph K Lim
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

3.  Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.

Authors:  Alexander J Millman; Boatemaa Ntiri-Reid; Risha Irvin; Maggie H Kaufmann; Andrew Aronsohn; Jeffrey S Duchin; John D Scott; Claudia Vellozzi
Journal:  Top Antivir Med       Date:  2017 Jul/Aug

4.  Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.

Authors:  Alexander J Millman; Noele P Nelson; Claudia Vellozzi
Journal:  Curr Epidemiol Rep       Date:  2017-04-20

5.  Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Authors:  Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

6.  The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.

Authors:  Harriet Ho; Naveed Z Janjua; Kimberlyn M McGrail; Mark Harrison; Michael R Law
Journal:  PLoS One       Date:  2021-03-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.